Compare Abeona Therapeutics Inc (ABEO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Neurocrine Biosciences Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Neurocrine Biosciences Inc trades at $179.5 (market cap $17.84B). The key difference: Neurocrine Biosciences Inc is far larger — about 47.8× Abeona Therapeutics Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NBIX | |
|---|---|---|
Market Cap | $373.32M | $17.84B |
Sector | Health | Health |
52-Week High | $7.23 | $177.49 |
52-Week Low | $4.17 | $123.10 |
Enterprise Value | $228.22M | $16.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Neurocrine Biosciences (NBIX) trades at $174.1, showing modest daily movement with a slight decline of 0.09%. The stock exhibits strong bullish technical signals from moving averages and a consensus analyst buy rating of 86.49%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.94 surpassing the $1.22 estimate. Revenue growth is robust, climbing from $2.86B in 2025 to a projected $3.1B in 2026, supported by blockbuster products Ingrezza and Crenessity.
NBIX presents a favorable outlook with upward earnings momentum and strategic acquisitions strengthening its neuroscience portfolio. Key risks include pipeline execution challenges and competitive pressures. The consensus price target of $192.91 suggests approximately 11% upside potential from current levels, making it an attractive growth stock despite elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
